Your session is about to expire
← Back to Search
VX-121/TEZ/D-IVA for Cystic Fibrosis
Study Summary
This trial looks at the effects of a new drug on people with moderate hepatic impairment, and compares them to healthy people.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment open for this research project?
"According to the info hosted on clinicaltrials.gov, this medical study is currently seeking suitable participants; it was initially shared on July 22nd 2022 and most recently updated August 4th 2022."
What is the current enrollment size for this research endeavor?
"Affirmative. Clinicaltrials.gov offers evidence that this clinical trial began recruitment on July 22nd 2022 and was recently modified on August 4th of the same year. Currently, 24 patients are required to be enrolled between two specific locations."
Has the FDA granted endorsement of VX-121/TEZ/D-IVA?
"After considering the information available, our experts at Power ranked VX-121/TEZ/D-IVA's safety as a 1. This is due to this being an early Phase 1 medical trial, so there are only limited data points regarding its efficacy and safety profile."
Who meets the criteria to take part in this medical experiment?
"This medical experiment is enrolling 24 individuals with cystic fibrosis that are between 18 and 70 years of age. The inclusion criteria also stipulates that participants must have a Child-Pugh score ranging from 7 to 9 points, chronic liver disease for at least 6 months, matched smoking habits, similar ages, sexes and weights relative to the hepatic impairment cohort."
Does this research trial accept participants of a younger age bracket?
"According to the criteria for eligibility, potential participants must be aged between 18 and 70. There are 69 trials that focus on younger patients below 18 years old and 99 specifically targeting those aged 65 or above."
Share this study with friends
Copy Link
Messenger